Background and Aims: Only a quarter of thiopurine-induced myelotoxicity in inflammatory bowel disease [IBD] patients is related to thiopurine S-methyltransferase deficiency. We determined the predictive value of 6-thioguanine nucleotide [6-TGN] and 6-methylmercaptopurine ribonucleotide [6-MMPR] concentrations 1 week after initiation [T1] for development of leukopenia during the first 8 weeks of thiopurine treatment.
Introduction
For both the immunomodulating thiopurine drugs azathioprine [AZA] and mercaptopurine therapeutic efficacy has been demonstrated with respect to induction and maintenance of remission in patients with inflammatory bowel diseases (IBD: Crohn's disease [CD] and ulcerative colitis (UC]). [1] [2] [3] Unfortunately, up to 25% of IBD patients discontinue thiopurine therapy during the first months of treatment due to adverse events. [4] [5] [6] The most important and potentially lethal adverse reaction to AZA/6-MP treatment is myelosuppression. A review of thiopurine-induced myelotoxicity in patients with IBD, including data from 66 trials [8302 patients], reported a 7% cumulative incidence of AZA/6-MP-induced myelotoxicity that predominantly occurred within the first weeks or months of treatment. 7 Azathioprine and 6-MP undergo extensive intracellular metabolic transformations to active metabolites, of which 6-thioguanine nucleotides and 6-methylmercaptopurine ribonucleotides are considered to be the most important [ Figure 1 ]. Interindividual differences in therapeutic response and toxicity to thiopurines can be explained by variation in the formation of these metabolites, which is partly related to genetic variants in the genes encoding for crucial enzymes in the thiopurine metabolism. 8 One of the key enzymes in the delicate balance between 6-MMPR and 6-TGN metabolite formation is thiopurine S-methyltransferase [TPMT] . 8 Eleven per cent of the Caucasian population is a heterozygous carrier of an inactive TPMT allele and 0.3% is homozygous for a TPMT variant, resulting in an intermediate and low/absent TPMT activity, respectively. Humans carrying two active alleles [~89%] show normal TPMT enzyme activity. Decreased TPMT enzyme activity shifts thiopurine metabolism towards increased formation of active cytotoxic 6-TGN metabolites. 9 Prior-to-treatment TPMT genotype or phenotype assessment may help to identify patients at risk of developing severe myelotoxicity. 8, 10 As in less than a quarter of the patients myelosuppression could be related to TPMT deficiency, the clinical usefulness of these assessments to avoid bone marrow toxicity seems to be limited. 11, 12 Recent results of the prospective randomized controlled TOPIC trial on pre-treatment TPMT screening demonstrated a 10-fold reduction in myelotoxic events among heterozygote variant carriers who were identified and treated with a reduced AZA or 6-MP dose, when compared with variant carriers treated with a standard dose. However, genotyping of the three most common genetic variants in TPMT [*2, *3A and *3C] only explained 16% of the cases of leukopenia. 13 Steady-state 6-TGN and 6-MMPR metabolite concentrations are generally reached after ~4-8 weeks of therapy. 14 The therapeutic range has been defined as a steady-state 6-TGN concentration between 235 and 490 pmol/8 × 10
8 red blood cells [RBCs] . 15, 16 The risk of leukopenia increases for 6-TGN steady-state concentrations higher than 490 pmol/8 × 10 8 RBCs, whereas 6-MMPR concentrations higher than 5700 pmol/8 × 10 8 RBCs are associated with hepatotoxicity. 14, 15, 17 In addition, extremely elevated 6-MMPR metabolites have also been associated with severe myelosuppression. [18] [19] [20] Therapeutic drug monitoring of thiopurine metabolites is a helpful tool in strategies to reduce toxicity. 21 Since myelosuppression is linked to toxic steady-state 6-TGN and 6-MMPR metabolite concentrations, we hypothesize that elevations of these metabolites may already be detectable before steady-state levels are reached. 14, 15, 22, 23 The aim of the present study was to evaluate the predictive value of 6-TGN and 6-MMPR metabolite concentrations [assessed 1 week after initiating thiopurine therapy] for the development of leukopenia during the first 8 weeks of thiopurine treatment.
Materials and Methods

Study design and outcome definition
The study was conducted in a subset of the patients from the TOPIC [Thiopurine response Optimization by Pharmacogenetics testing in Inflammatory bowel disease Clinics] trial, a randomized multicentre trial, including 769 IBD patients, that evaluated the effectiveness of pre-treatment TPMT genotyping. The TOPIC trial was approved by the Medical Ethics Committees of the participating centres. Written informed consent was obtained from all participating patients. The study is registered at clinicaltrials.gov [NCT00521950] .
For a detailed description of the study design and patient selection of the TOPIC trial we refer to Coenen et al. 13 Patients were enrolled by the TOPIC recruitment team [see Acknowledgments section for a list of TOPIC collaborators]. Patients meeting the inclusion criteria were randomly assigned to either standard thiopurine treatment [AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day] or a dose regimen based on the pre-treatment revealed TPMT genotype. Patients of the intervention group carrying a genetic variant were treated with 50% [heterozygous TPMT] or 0-10% [homozygous TPMT] of the standard thiopurine dose, according to the guidelines of the Dutch Pharmacogenetics Working Group. 24 All patients were clinically followed for 20 weeks after treatment initiation. Safety was evaluated by measurement of haematological and biochemical parameters 1 week before initiation and at least at weeks 1, 2, 4, 6, 8 and 20 after initiation of thiopurine therapy.
For the present study, blood samples for 6-TGN and 6-MMPR assessment were collected 1 week [i.e. ~7 ± 1 days] after thiopurine initiation [T1].
Leukopenia was defined by leukocyte counts of <3.0 × 10 9 /L. Thiopurine dose adjustments were defined as thiopurine dose escalation or reduction. Any decision regarding dose adjustments or discontinuation of thiopurine therapy was made by the responsible physician and was recorded.
For comparison, patients of the first consecutive 272 patients of the TOPIC trial who completed a follow-up period of 8 weeks without leukopenia on stable thiopurine dose were eligible. Patients with thiopurine dose adjustments or thiopurine discontinuation during the first 8 weeks that were not related to leukopenia [a leukocyte count of <3.0 × 10 9 /L] were excluded from the analysis. Thiopurine metabolite concentrations were assessed in the first 272 consecutive included IBD patients and in the remaining patients included in the TOPIC trial who developed leukopenia in the first 8 weeks after treatment initiation.
In this study, the association between 6-TGN and 6-MMPR metabolite concentrations and leukopenia was evaluated; therefore, dose reduction based on prior-to-treatment TPMT genotyping in the course of the TOPIC trial did not interfere with the primary outcome.
The design of the study and the flow chart for the patient selection are depicted in Figure 2. 
Measurement of 6-TGN and 6-MMPR metabolite concentrations
The 6-TGN and 6-MMPR metabolite concentrations were measured after the follow-up period of the TOPIC trial. The thiopurine metabolite concentrations were determined by the modified high performance liquid chromatography [HPLC] method of Lennard and Singleton, as published previously. 14 
Data analysis
Descriptive data analysis was in the form of percentages for categorical variables, and in the form of median values and ranges for continuous characteristics. Box-and-whisker plots were used in graphical representations. Differences in patient characteristics were evaluated using Pearson's chi-square or Fisher's exact tests; for 6-TUA, 6-thiouric acid; 6-MTIMP, 6-methylthioinosine monophosphate; 6-MTIDP, 6-methylthioinosine diphosphate; 6-MTITP, 6-methylthioinosine triphosphate; 6-TIMP, 6-thioinosine monophosphate; 6-TIDP, 6-thioinosine diphosphate; 6-TITP, 6-thioinosine triphosphate; 6-TXMP, 6-thioxanthosine monophosphate; 6-TGMP, 6-thioguanine monophosphate; 6-TGDP, 6-thioguanine diphosphate; 6-TGTP, 6-thioguanine triphosphate; 6-MTGMP, 6-methylthioguanine monophosphate; XO, xanthine oxidase; GST, glutathione S-transferase; TPMT, thiopurine S-methyl transferase; HGPRT, hypoxanthine phosphoribosyl transferase; IMPDH, inosine monophosphate dehydrogenase; GMPS, guanosine monophosphate synthetase; MPK, monophosphate kinase; DPK, diphosphate kinase; ITPase, inosine triphosphate pyrophosphatase; 6-TG, 6-thioguanine; 6-MTG, 6-methylthioguanine; 6-TX, 6-thioxanthine; 8-OHTX, 8-hydroxy-6-thioxanthine; GD, guanine deaminase; AO, aldehyde oxidase; PDNS, purine de novo synthesis; DNA, deoxyribonucleic acid; RNA, ribonucleic acid. 6-MTIMP, 6-MTIDP and 6-MTITP together form the 6-methylmercaptopurine ribonucleotides [6-MMPR]. 6-TGMP, 6-TGDP and 6-TGTP together form the 6-thioguaninenucleotides . Enzymes encoded by genes that are subject to known genetic polymorphisms are circled in grey.
differences in metabolite concentrations, the Mann-Whitney U test or Kolmogorov-Smirnov Z test were applied, when appropriate. A p-value of <0.05 [two-sided] was considered to be statistically significant. SPSS for Windows version 20.0 was used for all data analysis.
To study the discriminative power of 6-TGN and 6-MMPR concentrations regarding leukopenia, Receiver Operating Characteristic [ROC] curves were generated, which plot sensitivity rates and false positive rates [1 -specificity] regarding the occurrence of leukopenia. As a summary measure, the area under the ROC curves [AUC] and 95% confidence interval [95% CI] were calculated.
The predictive power of the metabolites for the development of leukopenia was studied by logistic regression modelling taking covariates into account such as age, gender, disease type [CD/UC], and medication [thiopurine type, thiopurine dose and concurrent use of known potential myelotoxic drugs or drugs interfering with thiopurine metabolism, e.g. mesalazine The results are expressed as odds ratios [ORs] with 95% confidence intervals.
Ethics approval
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Results
Baseline cohort analysis
Fourteen [5%] of the first 272 consecutive IBD patients included in the TOPIC trial developed leukopenia during the first 8 weeks. Ninety-six [37%] of the 258 patients without a leukopenic event were excluded from the analysis due to thiopurine dose adjustments [n = 36, 14%] or treatment discontinuation [n = 60, 23%] during the first 8 weeks, leaving 162 patients without leukopenia for evaluation. Eighteen patients of the remaining 497 patients [4%] included in the TOPIC trial developed leukopenia during the first 8 weeks of thiopurine therapy and were additionally included, resulting in a total number of 32 patients with leukopenia [ Figure 2 ].
The baseline characteristics of the leukopenic and non-leukopenic patient groups are given in Table 1 .
Overall, gender, age, IBD type, and thiopurine dose were similar in both patient groups.
The median time to onset of leukopenia was 4. in those treated with AZA. In addition, 6-MMPR concentrations were higher in women at week 1, compared with those in men. Concomitant treatment with systemic corticosteroids, 5-ASA, or anti-TNF-α treatment did not influence the 6-TGN or 6-MMPR concentrations at week 1 [ Table 2 ]. The predictive power for three cut-off values of 6-TGN and 6-MMPR concentrations at T1, set at specificity rates of 80, 90, and 95%, are presented in Table 3 . Odds ratios serve as an overall measure, whereas positive and negative likelihood ratios [true positive versus false positive and false negative versus true negative] facilitate medical practice. The ranges of OR, positive and negative likelihood ratios do not reveal preference for a specific threshold value. 
Prediction model for leukopenia, including thiopurine type and concurrent anti-TNF treatment
Discussion
In this prospective study we showed for the first time that elevated 6-TGN and 6-MMPR metabolite levels assessed 1 week after initiation are highly predictive for thiopurine-induced leukopenia during the first 8 weeks of thiopurine therapy in IBD patients. Almost 80% of the leukopenia cases were explained by elevated 6-TGN and/or 6-MMPR metabolite concentrations at week 1.
In previous studies the relation between thiopurine metabolites and leukopenia has been studied during steady-state maintenance therapy; however, leukopenia mostly occurs in the early stage of therapy, before steady-state concentrations are reached. 15, 20 Therefore, in clinical practice steady-state thiopurine metabolite concentrations are less useful for identifying patients at risk of developing leukopenia during the first weeks of treatment.
ROC analyses of the T1 6-TGN and 6-MMPR concentrations predicting leukopenia revealed an area under the ROC curve of 0.73 and 0.72, respectively, indicating a proper discriminative performance for both thiopurine metabolites.
Until now, myelotoxicity has mainly been attributed to elevated 6-TGN concentrations. 15, 17 Surprisingly, we observed that the predictive value for the occurrence of leukopenia of the 6-MMPR metabolites at week 1 is similar to that of the 6-TGN metabolites. Only a limited number of studies related the development of leukopenia to the methylated thiopurine metabolites. Hindorf et al. reported that the first methylated metabolite of the 6-MMPR, 6-methylthioinosine monophosphate , early in the steady-state phase was associated with myelotoxicity in IBD patients following a dose escalation schedule for AZA and 6-MP. 20 In addition, two case reports also indicated that extremely elevated 6-MMPR levels with subtherapeutic 6-TGN levels can cause severe myelosuppression. 18, 19 The interpretation of the findings from previous studies on the relation between thiopurine metabolites and myelotoxicity is complex because different definitions of leukopenia and myelosuppression were often used, and the association was mostly studied during various phases of thiopurine therapy. In addition, different thiopurine metabolites were evaluated, and they were determined by different analytical HPLC methods in a relatively small number of pat ients. 14, 15, 20, 25, 26 These factors make the data hard to compare and to apply in clinical practice.
The present study results show that both 6-TGN and 6-MMPR are independently correlated with leukopenia and that the cytotoxic effect of one is presumably enhanced by the other. The cytotoxic effect of the 6-TGN has been ascribed to them being incorporated into DNA, acting as fraudulent bases, resulting in strand breakage. 27, 28 In addition, the 6-MMPR, in particular the cytotoxic metabolite 6-MTIMP, have been shown to inhibit purine de novo synthesis [PDNS], leading to inhibition of DNA formation, decreased cell proliferation, and cytotoxic effects. 28, 29 AZA and 6-MP may mainly exert their cytotoxic effect through PDNS inhibition by 6-MTIMP, independently of 6-TGN formation. 28 The latter may explain, at least for a part, the fact that thiopurine-induced leukopenia is not always related to elevated 6-TGN concentrations due to low or absent TPMT enzyme activity.
Myelosuppression is often multifactorial or caused by other factors, such as viral infections [e.g. Parvovirus B19, Varicella zoster], medication causing myelosuppression by itself [e.g. captopril, metronidazole or trimethotrim-sulfamethoxazol], or medication interfering with thiopurine metabolism [i.e. allopurinol, mesalazine].
11,30
Viral infections have not been evaluated in our study, due to lack of data. We did evaluate concomitant IBD medication [mesalazine and anti-TNF therapy] in association with the occurrence of leukopenia. Concurrent treatment of 5-ASA has been demonstrated to result in elevated 6-TGN concentrations, which may lead to an increased risk for development of myelotoxicity. [31] [32] [33] In the present study we could not confirm this for metabolite concentrations at week 1 and the occurrence of leukopenia during the first 8 weeks of treatment. However, anti-TNF agents appeared to be an independent risk factor for leukopenia in patients concomitantly treated with thiopurines, while thiopurine metabolite concentrations at week 1 were not affected. Consequently, this finding indicates that the myelotoxic properties of thiopurines may be potentiated by additional myelotoxic effects of anti-TNF agents, as we have previously described for concurrent ADA therapy in a small CD patient group showing mainly low-therapeutic 6-TGN concentrations during thiopurine maintenance therapy. 34 This finding is clinically relevant because combined anti-TNF and thiopurine therapy seems to have beneficial therapeutic effects in the treatment of moderate-to-severe active IBD [35] [36] [37] and is recommended for minimizing the immunogenicity of anti-TNF monoclonal antibodies to prevent loss of response.
Some remarks should be made concerning our study design and patient selection. First, leukopenia was defined by a leukocyte count of <3.0 × 10 9 /L in order to study the relation between thiopurine metabolites and moderate-to-severe leukopenia. Unfortunately, we were unable to evaluate the 6-TGN and 6-MMPR metabolite concentrations during any leukopenic event. Second, patients for whom the thiopurine dose was adjusted by the clinician due to any adverse event not related to leukopenia were excluded from analysis. Consequently, patients whose dose was reduced due to a mild leukopenia [leukocyte count 3.0-4.0 × 10 9 /L] were not evaluated, possibly explaining the moderate sensitivity [both 59%] of the defined predictive 6-TGN and 6-MMPR threshold values for developing leukopenia. The moderate sensitivity rates may also be explained by the fact that the metabolite concentrations were assessed in erythrocytes, as a surrogate marker for the actual target cells, the leukocytes. Furthermore, patients who developed leukopenia after the follow-up period of 8 weeks of treatment were not evaluated. Third, in the present study patients treated with 6-MP were at higher risk of leukopenia, compared with patients treated with AZA. Although AZA and 6-MP in all patients were per protocol equivalently dosed [AZA 2-2.5 mg/kg/day and 6-MP 1-1.5 mg/kg/day], this observation may be partly explained by the fact that the concentrations of 6-TGN and 6-MMPR were both higher in patients treated with 6-MP. No difference in 6-MP dose [mg/kg] was observed between patients who did, or did not, develop leukopenia, which indicates that individual thiopurine metabolism is more important than the dose. 14 The formation of 6-TGN and 6-MMPR metabolites is often inversely related within each individual, so that the predictive value of one may be affected by the other. In addition, patients treated with 6-MP and concurrent anti-TNF therapy were more likely to develop leukopenia. Multivariable regression analysis of these determinants revealed that patients with both 6-TGN and 6-MMPR above the predictive threshold concentrations had a highly increased risk of leukopenia, followed by that of patients with either 6-TGN or 6-MMPR levels above the defined thresholds at week 1. Patients on concurrent anti-TNF therapy with elevated T1 6-TGN and 6-MMPR levels all developed leukopenia. Consequently, based on different combinations of the aforementioned parameters, patients can be classified using this accurate predictive algorithm [AUC = 0.84] to assess the degree of risk for the development of thiopurine-induced leukopenia.
Early identification of patients at increased risk of leukopenia is important because it may reduce morbidity and hospitalization, or even mortality.
Over the past decade, the usefulness of pre-treatment TPMT geno-or phenotyping in daily practice has frequently been debated. Since TPMT genotyping is the more reliable test, especially in TPMT heterozygotes, it has been suggested that genotyping should be considered the primary choice for pre-treatment TPMT screening. 38 Prior-to-treatment TPMT genotype-based dosing results in a significant reduction in leukopenia in IBD patients carrying a genetic TPMT variant, importantly without loss of treatment efficacy. 13 Diagnostic test results should generally be obtained within 5-10 working days by using proper logistic arrangements. Furthermore, the cost-effectiveness has repeatedly been stated. 39 On the other hand, TPMT testing only explains a small part of thiopurine-induced myelotoxicity. [11] [12] [13] Thiopurine metabolism is complex and unpredictable due to the involvement of the great variety of metabolic enzymes, of which TPMT is only one. 8 In the present study we demonstrated that thiopurine-induced leukopenia also strongly correlated with elevated 6-MMPR metabolites. TPMT screening only gives the clinician information about a possible excessive 6-TGN formation, but nothing about the rate of 6-MMPR metabolite formation. 40 Patients who show excessive 6-MMPR formation resulting from a skewed metabolism are also at risk for early thiopurine failure due to intolerable adverse events or refractoriness. 41 In these cases, precautionary measures can be taken by reducing the thiopurine dose to 25-30% in combination with 100 mg allopurinol per day 42 or by a switch to 6-thioguanine [0.3 mg/kg bodyweight per day, max. 25 mg per day; Figure 1 ], which has been proposed as an alternative thiopurine in IBD patients failing to tolerate or to respond to conventional thiopurine therapy. 43 Assessment of thiopurine metabolites at week 1 is an attractive way to reveal a patient's 'ultimate phenotype', displayed by the most important active metabolites, 6-TGN and 6-MMPR.
In future research, the proposed algorithm should be validated in a prospective randomized controlled intervention study evaluating whether optimizing strategies based on the T1 metabolite profile will prevent the occurrence of leukopenia. Until then, complementary to pre-treatment TPMT testing, T1 thiopurine metabolite assessment may be helpful for identifying patients at risk of developing leukopenia due to high cytotoxic 6-TGN and 6-MMPR concentrations resulting from causes other than a TPMT deficiency, such as overdosing or a skewed thiopurine metabolism. Intensive safety monitoring and adequate thiopurine dose reduction is then advocated.
Therapeutic drug monitoring during steady state can be used to evaluate pharmacological action, for dose optimization purposes or to evaluate patient compliance.
In conclusion, both 6-TGN and 6-MMPR metabolites accurately predict the occurrence of leukopenia during the first 8 weeks of therapy. Assessment of 6-TGN and 6-MMPR metabolite concentrations 1 week after thiopurine initiation helps to identify patients at risk of developing thiopurine-induced leukopenia.
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